Pfizer Reaffirms FY23 Outlook - Update

(RTTNews) - While reporting financial results for the third quarter, drug major Pfizer Inc. (PFE) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.

For fiscal 2023, the company continues to project adjusted earnings in a range of $1.45 and $1.65 per share on revenues between $58.0 billion and $61.0 billion, with revenues of about $11.5 billion for Comirnaty and about $1 billion for Paxlovid. Excluding COVID-19 products, the company still expects 6 to 8 percent operational revenue growth.

The Street is looking for earnings of $1.50 per share on revenues of $55.37 billion for the year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com